T-Dxd Redefining HER2+ Metastatic Care: From 85% Response Rates to Brain Metastasis Breakthroughs

With systemic response rates nearing 85%, T-DXd is setting a new benchmark in metastatic HER2+ breast cancer. But the impact doesn’t stop there.

Drs. Pegram and Yan discuss why T-DXd is a dual-threat—delivering both systemic control and remarkable intracranial activity. Listen in as they explain why these results are fundamentally changing the treatment paradigm for patients with and without brain metastases.